Ipamorelin’s literature includes early growth-hormone pharmacology, human concentration–response modelling and a clinical investigation of postoperative bowel recovery. A useful reference includes this range rather than treating the phrase selective secretagogue as a complete description of its evidence. The studies below show where the molecule was examined and what each actually measured.
Retain the non-standard residues and terminal notation
Raun and colleagues’ 1998 paper identifies ipamorelin as Aib-His-D-2-Nal-D-Phe-Lys-NH2. This five-residue description includes non-standard residue notation, D stereochemistry and an amidated terminus.Raun and colleagues — Ipamorelin, the first selective growth hormone secretagogue (opens in a new tab)
| Detail | Reading consequence |
|---|---|
| Aib and D-2-Nal | Do not replace these with ordinary one-letter residue guesses |
| D-Phe | The stereochemical designation belongs to the identity |
| Terminal NH2 | The stated peptide is amidated |
A simplified sequence that removes these details can describe a different intended structure. Preserve the original notation when linking the molecule to a paper or reference material.
This is particularly useful when a database search retrieves related growth-hormone-releasing peptides. Sharing a pharmacological category does not mean sharing ipamorelin’s complete identity.
Read the early selectivity claim within its experiments
The 1998 work examined growth-hormone release in rat pituitary cells and animal systems. Its swine comparisons found a different ACTH/cortisol response profile for ipamorelin than for some comparator secretagogues.Raun and colleagues — Ipamorelin, the first selective growth hormone secretagogue (opens in a new tab)
The word selective in that paper refers to the hormonal comparisons and conditions investigated. It is not a demonstration that ipamorelin has no other biological effects, nor that adverse effects cannot occur.
An especially misleading shortcut would turn a result about selected hormone measurements in swine into a statement of universal human safety. The species, measurements and comparison must stay attached to the conclusion.
Distinguish a human hormone response from a clinical benefit
Gobburu and colleagues’ 1999 study measured ipamorelin and growth-hormone concentrations in healthy male volunteers. It used pharmacokinetic–pharmacodynamic modelling to relate exposure to an episode of hormone release.Gobburu and colleagues — Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens in a new tab)
The investigators reported greater between-person variability in response parameters than in the pharmacokinetic parameters. A concentration profile and a hormone response were therefore related measurements, not interchangeable descriptions.Gobburu and colleagues — Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens in a new tab)
This paper adds human pharmacology to the evidence map. It does not answer whether a repeated-use programme improves an everyday functional outcome or establishes an appropriate regimen for a catalogue product.
When extracting its findings, keep the measured molecule concentration, the measured hormone and the fitted model as separate fields. A model summarises the observed relationship under its assumptions; it is not a direct measurement of every future person’s response.
Include the postoperative study’s inconclusive efficacy result
Beck and colleagues’ 2014 phase 2 study examined patients after bowel resection in a randomised, double-blind, placebo-controlled design. It enrolled 117 patients, with 114 in the reported safety and modified intention-to-treat populations.Beck and colleagues — Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (opens in a new tab)
Its key efficacy measure concerned time to tolerance of a standardised solid meal. The paper reported no significant difference between groups in the key or secondary efficacy analyses.Beck and colleagues — Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (opens in a new tab)
A numerical difference between group summaries should not be reported as demonstrated clinical success when the study’s analysis did not establish that conclusion. Equally, this one small trial does not prove that every possible effect of the molecule is absent.
| Study | Primary role here |
|---|---|
| Raun 1998 | Identity and experimental hormone-response profile |
| Gobburu 1999 | Human exposure and hormone-response modelling |
| Beck 2014 | Clinical comparison after bowel surgery |
Together these references show why a balanced ipamorelin introduction needs both positive pharmacological observations and an efficacy comparison that did not establish a difference. None of the three papers tests the current Novum research vials or validates a blended formulation.
Sources and further detail
- Raun and colleagues — Ipamorelin, the first selective growth hormone secretagogue (opens in a new tab)
Original 1998 abstract and author metadata checked for sequence, models and bounded hormonal comparison. No potency values, administration procedures or universal safety claim reproduced.
- Gobburu and colleagues — Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens in a new tab)
Original 1999 abstract and metadata read. Brief exposure/response and variability description; no half-life-based regimen or dosing guidance.
- Beck and colleagues — Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (opens in a new tab)
Original 2014 abstract and authors read. Enrolled versus analysis populations distinguished; non-significant efficacy conclusion retained. No clinical-use recommendation.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.